Innate Secures $75M Sobi Deal
Innate Pharma secures a $75 million Sobi partnership to advance cancer immunotherapy trials.
Anonymous
Key Points
1
The FDA has cleared TELLOMAK-3’s dual-cohort design: a confirmatory cohort in Sézary syndrome and a registrational cohort in mycosis fungoides.
2
Lacutamab has received several regulatory designations intended to facilitate development, including FDA breakthrough therapy and fast-track status, the EMA’s PRIME designation, and orphan-drug designations in the United States and Europe.
3
Innate said its cash runway is projected to extend through the first quarter of 2028, although management cautioned that the company remains dependent on early-stage clinical progress and may require additional funding.
4
If accelerated approval is granted, Sobi would receive exclusive global commercialization rights to lacutamab; Sobi could assume full global development rights after positive Phase 3 results.
5
Innate estimates that the combined U.S. market opportunity for lacutamab in mycosis fungoides and Sézary syndrome could reach as much as $500 million.
Innate Pharma closed a major partnership with Swedish Orphan Biovitrum (Sobi) for its cancer drug lacutamab, securing a $75 million upfront payment plus potential future milestone payments of up to $505 million. TipRanks reported that the deal advances the company's immunotherapy pipeline while extending its cash runway into early 2028.
The company plans to dose patients in a pivotal Phase 3 trial called TELLOMAK-3 in early 2027 and seek accelerated approval for Sézary syndrome by late 2027. HC Wainwright maintained a Buy rating on the stock, raising long-term earnings forecasts as the partnership strengthens Innate's financial position.
What Lacutamab Treats and How It's Advancing
Lacutamab targets cutaneous T-cell lymphoma, a rare blood cancer affecting the skin. The FDA cleared a dual-cohort trial design with one group testing the drug in Sézary syndrome and another in mycosis fungoides. TipRanks noted that the drug has received breakthrough therapy status, fast-track designation, and orphan-drug protections from regulators.
The Cash Boost and Market Opportunity
The $75 million upfront payment provides immediate capital. Innate is eligible for $40 million in near-term milestones and up to $465 million more based on regulatory and sales achievements, plus double-digit royalties on future sales. The company estimates the combined U.S. market for both diseases could reach $500 million.
Timeline and Regulatory Path to Launch
If accelerated approval is granted, Sobi will have exclusive global commercialization rights. Seeking Alpha reported that the company expects to file for accelerated approval in the second half of 2027 based on existing Phase 2 data. Should Phase 3 results succeed, Sobi could assume full global development rights to the drug.
Financial Risk and Remaining Uncertainties
Despite the partnership boost, Innate remains an early-stage biotech company with significant risks. HC Wainwright cautioned that cash extends only to early 2028, meaning Innate may need more funding if trials slip. Development delays, regulatory rejection, or commercialization challenges could derail the program and trigger additional capital raises that dilute shareholders.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
23
Articles
86
Reach
109
A
AnonymousAuthor
